Plenary Session 2: Panel discussion on new regulatory guidelines on RWD, rare disease, biomarker, and Bayesian statistical methods

3:20-4:50 PM, November 23, 2026; Room 10A-D

Moderator
Panelists

Yuan Ji

Moderator: The University of Chicago
Biography

Yuan Ji

Yuan Ji is Professor of Biostatistics at The University of Chicago. His research focuses on innovative Bayesian statistical methods for translational cancer research. He is the inventor of Bayesian adaptive designs such as the mTPI and i3+3 designs, which have been widely applied in dose-finding clinical trials worldwide. His work on cancer genomics was reported by numerous media outlets in 2015. He received the Mitchell Prize from the International Society for Bayesian Analysis in 2015 and is an elected Fellow of the American Statistical Association.


Jie Chen

Panelist: Taimei Intelligence Biopharma R&D Ltd.
Biography

Jie Chen

Jie Chen is Chairman and Chief Scientific Officer of Taimei Intelligence Biopharma R&D Ltd. With more than 30 years of experience in biopharmaceutical research and development, he has contributed to the design, analysis, and regulatory submission of more than 50 clinical trials, supporting the approval of over 10 drugs across oncology, cardiovascular, infectious diseases, and other therapeutic areas. He previously held senior roles at Merck, Merck Serono, Novartis, AstraZeneca, and Overland Pharmaceuticals. An elected Fellow of the American Statistical Association and an active leader in real-world evidence and artificial intelligence, Dr. Chen serves as an industry doctorate advisor in public health at Fudan University. He has authored more than 60 peer-reviewed papers and three books.


Yuki Ando

Panelist: Principal Senior Scientist for Biostatistics, Pharmaceuticals and Medical Devices Agency, Japan
Biography

Yuki Ando

Dr. Yuki Ando is a Principal Senior Scientist for Biostatistics at the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. She has over 20 years of experience in the biostatistical review of pharmaceutical and medical device products and currently leads biostatistical review and consultation for new drug and medical device applications at PMDA.

In addition to her regulatory review responsibilities, she contributed to several projects across multi-offices in PMDA, including the Real-World Data (RWD) Working Group and the Multi-Regional Clinical Trials (MRCT) Working Group. She also played a leading role in regulatory and standardization efforts related to the submission and utilization of electronic study data in new drug applications.

Dr. Ando previously served as a member of the ICH E9(R1) and E8(R1) Expert Working Groups (EWG) and is currently contributing to the development of ICH E20 as a member of the EWG.

She received a Master's degree in Engineering from Tokyo University of Science and a Ph.D. in Health Sciences from Osaka University.


Ying Yuan

Panelist: The University of Texas MD Anderson Cancer Center
Biography

Ying Yuan

Ying Yuan is the Bettyann Asche Murray Distinguished Professor and Chair of the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. Dr. Yuan is internationally renowned for his pioneering research in innovative Bayesian adaptive designs, including early-phase trials, seamless trials, biomarker-guided trials, hybrid control trials, Bayesian borrowing of historical data, and surrogate endpoints. The designs and software developed by Dr. Yuan’s lab (www.trialdesign.org) have been widely adopted by medical research institutes and pharmaceutical companies. Among these, the BOIN design, developed by Dr. Yuan’s team, is a groundbreaking oncology dose-finding method recognized by the FDA as a fit-for-purpose drug development tool. The BOP2 design is also widely used for efficacy and toxicity monitoring in early phase trials. Dr. Yuan is a member of the FDA Advisory Committee for Genetic Metabolic Diseases, an elected Fellow of the American Statistical Association, and the lead author of two books: Bayesian Designs for Phase I-II Clinical Trials and Model-Assisted Bayesian Designs for Dose Finding and Optimization, both published by Chapman & Hall/CRC.


Susan Halabi

Panelist: Duke University Medical Center
Biography

Susan Halabi

Susan Halabi, PhD, is the James B. Duke Distinguished Professor of Biostatistics and Bioinformatics and Co-Chief of the Division of Biostatistics, Department of Biostatistics and Bioinformatics at Duke University Medical Center. For more than 25 years, she has been a leader in the design and analysis of oncology clinical trials, developing innovative statistical methods for clinical studies, biomarkers, and high-dimensional data. Her research has made significant contributions to prognostic modeling in prostate cancer and the identification and validation of surrogate endpoints for overall survival. Dr. Halabi has authored more than 330 peer-reviewed publications and co-edited two foundational books, Oncology Clinical Trials (2nd Edition, Demos, 2018) and Textbook of Clinical Trials in Oncology (CRC Press, 2019). A past president of the Society for Clinical Trials, she is a Fellow of the Society for Clinical Trials, the American Statistical Association, and the American Society of Clinical Oncology, and has received numerous prestigious awards for her contributions to biostatistics and oncology research.


Justine Rochon

Panelist: Senior Vice President, Head of R&D Data and Quantitative Sciences, Takeda
Biography

Justine Rochon

Dr. Justine Rochon leads Takeda's R&D Data and Quantitative Sciences organization, advancing data-driven decision-making across quantitative pharmacology, translational sciences, patient safety and pharmacovigilance, clinical data sciences, advanced statistics, and AI integration. A psychologist and biostatistician with more than 20 years of experience in academia and industry, she holds a doctorate from the Medical Faculty of Heidelberg University. Dr. Rochon champions the responsible use of AI in drug development and co-authored the Charter for Data Science in Pharmaceutical R&D and the Manifesto for AI-Driven Clinical Trials.

She is a former President of EFSPI (European Federation of Statisticians in Pharmaceutical Industry), serves on the ASA Biopharmaceutical Section Executive Board, co-founded the DISRUPT-DS (Data Science) Roundtable, and was named a 2025 Trailblazing Woman in Pharma by Reuters.

LinkedIn profile


Back to agenda · Plenary Session 1